Verition Fund Management
RLMD icon

Verition Fund Management’s Relmada Therapeutics RLMD Stock Holding History

Verition Fund Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34,334
Closed -$103K – 2627
2023
Q3 		$103K Sell
34,334
-366
-1% -$1.09K ﹤0.01% 2116
2023
Q2 		$85.4K Buy
+34,700
New +$95.9K ﹤0.01% 1996

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verition Fund Management's RLMD Position: Q4 2023 in Review

Verition Fund Management sold out of Relmada Therapeutics (RLMD) in Q4 2023, closing a stake of 34,334 shares — an estimated $103K sold.

Verition Fund Management first reported a position in RLMD in Q2 2023 and held it in 2 quarters. The position peaked at $103K in Q3 2023. 83 funds tracked by Wall St. Rank hold RLMD as of Q4 2023.

  • Verition Fund Management reported no remaining Relmada Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Verition Fund Management sold 34,334 Relmada Therapeutics shares in Q4 2023, an estimated $103K.
  • Verition Fund Management first reported a position in Relmada Therapeutics in Q2 2023 and held it in 2 quarters.
  • Verition Fund Management's Relmada Therapeutics position peaked at $103K in Q3 2023.
  • 83 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2023.

Based on Verition Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.